being and becoming in the world
The launch in the UK of Lurisidone began in August 2014. My previous post on Lurasidone (Latuda) which has now been marketed in the UK followed the financial interests of … Continue reading Lurasidone [Latuda]: vigorously marketed in the UK
I noticed this “Special Article” published in the October edition of the British Journal of Psychiatry. It details a novel antipsychotic medication called Lurasidone (trade name Latuda). I would anticipate … Continue reading Lurasidone: “Special Article”
In my last post I considered the level of transparency provided by the British Association for Psychopharmacology (BAP) in relation to its recently published Guidelines on prescribing for depressive disorders. … Continue reading Stephen Stahl: $3,581,159 in payments from Pharma
There is a lot of effort in NHS Scotland to raise awareness among healthcare staff about delirium, using statements like this: Delirium is a very complex state and it is … Continue reading Yellow socks and handstands
In this post I reply to Professor Jason Leitch, whose letter of the 2nd June 2015 on Haloperidol prescribing to Scotland’s elderly I have included below my reply. Links included … Continue reading A letter to Professor Jason Leitch
This week the Cabinet Secretary for Health, Wellbeing and Sport welcomed a new report into management of frailty and delirium This reminded me, that 6 months on, I do not … Continue reading It is very difficult to challenge a powerful organisation
In a previous post the FOI returns on Haloperidol prescribing in NHS Scotland were shared. This followed on from my consideration of a BMJ report regarding the scale and potential … Continue reading Haloperidol prescribing to Scotland’s elders
This leter has been published in the current edition of The BMJ: Reading this letter my thoughts returned to a lecture given by Professor Allan Young at a Royal College … Continue reading “A huge number of ‘bipolars’ are missed”